Reva Medical has announced the commercial expansion of its bioresorbable scaffold Fantom, with the first implantation of the device in Switzerland. The procedure was conducted at Kantonsspital Baselland in Liestal, Switzerland by Gregor Leibundgut. Fantom, a press release reports, is the only bioresorbable scaffold made from Tyrocore, Reva’s proprietary tyrosine-derived polymer designed specifically for vascular scaffold applications. Tyrocore is inherently radiopaque, making Fantom the first and only scaffold that is visible under fluoroscopy.
The press release adds that Fantom provides thin 125micron struts while retaining radial strength, noting that thinner struts have been shown to improve deliverability and support vessel healing. Imaging data from the FANTOM II study showed that vessel patency was maintained at six and nine months with 0% malapposition and 99% strut coverage.
Leibundgut comments: “Following my experience with Fantom, I have been able to see first-hand how Fantom’s technology with the Tyrocore polymer offers simplified deliverability, single-step inflation for ease of use, and radiopacity for accurate scaffold placement. Bioresorbable scaffolds have the potential to offer comparable short-term treatment without the long-term complications of a permanent metallic stent. This is an important treatment option and we are happy to offer it to our patients.”
“Fantom, made with Reva’s novel polymer called Tyrocore, is an exciting advancement in bioresorbable scaffold technology that has the potential to positively impact clinical practice for physicians and patients. With the launch of Fantom in Switzerland, Reva continues to execute on our growth plan with direct selling efforts in the first phase of Fantom’s targeted launch,” says Reggie Groves, CEO, Reva Medical.
